Italia markets closed

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
25,19-0,13 (-0,51%)
Alla chiusura: 04:00PM EDT
24,12 -1,07 (-4,25%)
Dopo ore: 06:16PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente25,32
Aperto25,51
Denaro25,17 x 200
Lettera25,31 x 200
Min-Max giorno25,19 - 25,69
Intervallo di 52 settimane20,87 - 34,28
Volume753.925
Media Volume1.607.450
Capitalizzazione2,608B
Beta (5 anni mensile)0,47
Rapporto PE (ttm)26,80
EPS (ttm)0,94
Prossima data utili01 mag 2024 - 06 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A42,80
  • GlobeNewswire

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended June 30, 2023. Financial Results Revenue of $117.7 million, a 14 percent increase from second quarter 2022Increase in 2023 revenue guidance to $4

  • GlobeNewswire

    Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 2, 2023. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and

  • GlobeNewswire

    Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

    Phase 1b study demonstrates that miricorilant, a selective cortisol modulator, effectively reduces liver fat, improves liver health and key metabolic and lipid measures and is well-toleratedCorcept will initiate a Phase 2b study in the fourth quarter MENLO PARK, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology